Skip to content
Posts
- Kalohexis Appoints Life Sciences Leader, Jeffrey Sherman, MD, to Board of Directors – 11 August 2026
- Kalohexis Presents Data Demonstrating Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates at ICO 2026 – 15 July 2026
- Kalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering – 7 July 2026
- Kalohexis Appoints Xuan Hui, B.Med., M.S., Ph.D., as Director of Corporate Strategy – 18 June 2026
- Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026 – 15 June 2026
- Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight Loss – 29 May 2026
- Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity – 28 May 2026
- Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 – 17 April 2026
- Kalohexis Appoints Tony Mitchell as Chief Financial Officer – 31 March 2026
- Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity – 25 March 2026
- Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases – 19 March 2026
- Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in Obesity – 2 October 2025
- Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal Cancer – 30 April 2025
- Endevica Bio to Start Phase 2 Clinical Trial of Drug to Prevent Weight Loss in Cancer Patients – 20 December 2024
- Endevica Bio Drug Candidate Shows Promise for Alleviating Chemotherapy-Induced Anorexia and Weight Loss, Study Shows – 12 November 2024
- Endevica Bio drug candidate shows success in weight loss in new study – 23 April 2024
